Pandemic flu and the anti-H1N1 vaccine:
a retrospective view.
Albert OsterhausHead Dept Virology
Chairman ESWICSO Viroclinics-Biosciences BV
ESCMID conference on the impact of vaccines on
Public HealthPrague, 2nd April 2011
ESCMID Online Lecture Library
© by author
Human influenza: three appearances
Seasonal influenza(A: H3N2, H1N1; B)
Avian influenza(A: H7N7, H5N1…)
Pandemic influenza(A: H1N1, H2N2, H3N2, H1N1…?)ESCMID Online Lectu
re Library
© by author
INFLUENZA A VIRUS
Subtype
H7N7H5N1H9N2H5N1H7N7H7N2H7N3H5N1
Country
UKHongkongSE-AsiaHongkongNetherlandsUSACanadaSE-Asia/M-East/Europe/W-Africa
Year
1996199719992003200320032004
2003-11
# Cases
118>22?8912
.>500
# Deaths
0601100
>300*
Recent zoonotic transmissions
*CFR ~ 60%
ESCMID Online Lecture Library
© by author
Confirmed H5N1 avian influenza virus endemic areas (poultry and wild birds) since 2003
ESCMID Online Lecture Library
© by author
Avian influenza A H5N1 virus- HA: Receptor specificity -
Shinya et al., Nature 440, 2006
Van Riel et al.,Science 2006
Van Riel et al., Am J Pathol 2007
Van Riel et al., Am J Pathol 2009
Van Riel et al., Am J Pathol 2010ESCMID Online Lectu
re Library
© by author
Pandemic H1N1Seasonal H3N2
HPAIV H5N1
Introduction- Attachment to the upper respiratory tract -
ESCMID Online Lecture Library
© by author
Last four pandemics
A(H1N1) A(H2N2) A(H3N2)
1918
“Spanish Flu”
1957
“Asian Flu”1968
“Hong Kong Flu”
>40 million deaths 1-4 million deaths 1-4million deaths
Credit: US National Museum of Health and Medicine
2009
”Swine Flu”
???
A(H1N1)ESCMID Online Lecture Library
© by author
PB2,PA:
PB1:
~ 1998
~ 1968 ~ 1998
HA, NP, NS:~ 1918
NA, MA:~ 1979
PB2PB1PAHANPNAMANS
N-America
Eurasia
Classical swine
Eurasian swine
Triple reassortant
A/California/4/2009
The H1N1v flu virusCourtesy: Ron FouchierESCMID Online Lectu
re Library
© by author
11
The Flu OrphansChildren in the Alaskan village of Nushagak survived
the Spanish flu of 1918
Alaska State Library
7
48
124
71
26 26
0
20
40
60
80
100
120
140
Mor
talit
ite
0-4 Yrs 5-24 Yrs 25-49 Yrs 50-64 Yrs ≥65 Yrs UnknownAge Groups
2%
16%
9% 9%
41%
24%
`2009 pandemic
ESCMID Online Lecture Library
© by author
Avian influenza A virus- Adaptation -
E. De Wit & R.A.M. Fouchier, J Clin Virol (2008)E. De Wit, Y. Kawaoka, M.D. De Jong & R.A.M. Fouchier, Vaccine (2008)E. De Wit E, Munster VJ, van Riel D, et al., J.Virol 2010 HA
NA
NS1
PB1, PB2, PA, NP
ESCMID Online Lecture Library
© by author
2009 influenza A (H1N1) virus:relevant mutations
Virulence associated substitution in HA: D222G(Herfst et al., J.Virol. 2010)
Oseltamivir resistance substitution in NA: H275Y(de Vries et al., J.Clin Microbiol. 2010)
Zanamivir resistance substitution in NA: I223R(de Vries et al NEJM 2010)
ESCMID Online Lecture Library
© by author
2009 influenza A (H1N1) virus:relevant mutations
Virulence associated substitution in HA: D222G(Herfst et al., J.Virol. 2010)
Oseltamivir resistance substitution in NA: H275Y(de Vries et al., J.Clin Microbiol. 2010)
Zanamivir resistance substitution in NA: I223R(de Vries et al NEJM 2010)
ESCMID Online Lecture Library
© by author
2009 pandemic Influenza associated ARDS
Despite the relative mildness of this pandemic, severe illness and death did occur.After the first influenza wave countries reported frequent ICU admissions, often in younger individuals.Most of the admitted individuals had serious underlying medical conditions, about 30% did not.ARDS was often associated with shock and DIC.
In USA 300,000 – 2,000,000 years lost (vaccination!!!)
Davies A et al JAMA, Dominguez-Cheritet et al JAMA, Jain S et al N Engl J Med 2009
ESCMID Online Lecture Library
© by author
INFLUENZA: are we prepared?- medical interventions –
SurveillanceHumans and animals: “early warning” en “rapid response”
Antiviral therapypreventive and therapeutic…resistance development ???
VaccinationCornerstone of prevention !!!
ESCMID Online Lecture Library
© by author
Seasonal H1N1 pH1N1 2009 HPAI H5N1
Temperature Virus Load
DIAGNOSTIC READ-OUTS
Clinical & Virological Parameters
Lung Weight
Munster et al., Science 2009
Del Giudice et al., Science TM 2009
Chutinimitkul et al., J.Virol 2010
Herfst et al., Vet.Pathol. 2010
Bosch et al., J.Virol. 2010
Kreijtz et al., J.Gen.Virol. 2010
v.d.Brand et al., JID 2010
v.d.Brand et al., J.Virol 2010
ESCMID Online Lecture Library
© by author
Whole virus Split virus`
Subunit(surface antigen)
Live attenuated
Baxter (Austria)Omnivest (Hungary)
8 manufacturers in ChinaCSL (Australia)Sanofi Pasteur (France)Green Cross (Korea)GSK Biologicals
Novartis (US) MedImmune (US)Microgen (Russia)
Examples of licensed monovalent pandemic influenza H1N1v vaccines
WHO. Marie-Paule Kieny. Update of the development of A(H1N1) pandemic influenza vaccines. November 9, 2009
ESCMID Online Lecture Library
© by author
Future generations:avian and pandemic influenza vaccines
Several novel generations of influenza vaccines are being developed(adjuvanted, DNA, LAIV, vectored, VLP, and protein / peptide-based …vaccines)
Novel adjuvants have led to flu vaccine candidates against avian influenza (H5,H9…)and pandemic flu that are Ag-sparing and broadly active
Vectored vaccines are promising next generation flu vaccine candidates
LAIV is used for seasonal vaccination and is a promising pandemic vaccine candidate
ESCMID Online Lecture Library
© by author
HLA-A1, A2, B8, B35
HLA-A1, A3, B8, B35
HLA-A1, A2, B8, B27
In vitro expanded T lymphocytes (influenza virus A/Ned/18/94 (H3N2))
BLCL infected with influenza H3N2 or H5N1 virus
IFNγ ELISPOT assay
Kreijtz et al. J Virol 2008, 82(11):5161-5166
Cross reactivity of human virus specific CTL
-Virus infected cells-
ESCMID Online Lecture Library
© by author
Vaccination against H3N2 prevents induction of heterosubtypic immunity by H3N2 infection
against fatal H5N1 infection
Kreijtz et al., Hum Vaccin. 2009 Bodewes et al ., Plos One 2009Bodewes et al ., Lancet 2010Bodewes et al ., J.Virol 2011
ESCMID Online Lecture Library
© by author
Vaccination against H3N2 prevents induction of heterosubtypic immunity by H3N2 infection
against fatal H5N1 infection
Kreijtz et al., Hum Vaccin. 2009 Bodewes et al ., Plos One 2009Bodewes et al ., Lancet 2010Bodewes et al ., J.Virol 2011
Q: universal flu vaccination of children?
ESCMID Online Lecture Library
© by author
Adjuvanted influenza vaccines / candidates
Approved:MF59 (squalene emulsion) seasonalAS03 (squalene/tocopherol emulsion) pandemic Virosomes (liposomes) seasonalPolyoxidonium (poly-electrolyte)seasonal
Clinical studies (phase 1, 2)Iscoms (with virosomes)AF3 (squalene o/w emulsions)SE (squalene o/w emulsions)GLA (TLR 4 agonist)Covaccine (TLR 4 agonist)Flagellin (TLR 5 agonist)IC31 (dI:dC – TLR9 agonist)Inulin (complement activator)JVRS-100 (cationic liposome)
ESCMID Online Lecture Library
© by author
Assessment of pre-pandemic H5N1 clinical trials
Type of vaccine Compliance with EU licensing criteria
Split vaccine no adjuvant Need two doses of 90 µg
Split/subunit vaccine with alum Need two doses of 30-45 µg
Whole virus (egg) with alum Need two doses of 10-15 µg
Subunit with MF59 adjuvant Need two doses of 7.5 µg
Whole virus Vero cell culture, no adjuvant Need two doses of 7.5 µg
Split vaccine with AS adjuvant Need two doses of 3.8 µg
Data presented at WHO meeting, February 2007(Sanofi Pasteur, 4 Companies in Jp, CSL, Microgen, Sinovac, GSK, Novartis,Baxter)
ESCMID Online Lecture Library
© by author
CHMP criteria
40
IX International Symposium on Respiratory Viral Infections ; March 3 – 6, 2007, Hong Kong
0
25
50
75
100
Post first dose Post second dose
Sero
conv
ersi
on ra
te (%
)3.8µg H5 7.5µg H5 15µg H530µg H5
3.8µg H5 AS7.5µg H5 AS15µg H5 AS30µg H5 AS
The three CHMP criteria are exceeded by all the adjuvanted doses: seroconversion rates
ESCMID Online Lecture Library
© by author
• 2 immunisations of ferrets at D0 and D21 (H5N1 A/Vietnam/1194/04 split / AS)• Heterologous challenge (wild-type virus A/Indonesia/5/05, 105 TCID50) at D49• Post challenge results at D5
Dead Alive % SurvivalPooled controls(15 µg Antigen
only or AS only)
12 0 0
1.7 µg H5N1 – AS 1 5 833.8 µg H5N1 – AS 0 6 1007.5 µg H5N1 – AS 0 5 10015 µg H5N1 – AS 0 6 100
Ferrets vaccinated with AS-adjuvanted H5N1 split candidate vaccine
Baras et al., PLoS One 2008 NB: similar data with clade 2.2 and 2.3 viruses
ESCMID Online Lecture Library
© by author
Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets B. Baras et al., Vaccine. 2011
ESCMID Online Lecture Library
© by author
Del Guidice et al. Science TM 2009
v.d.Brand et al J.Virol. 2010
Seasonal vaccine provides priming against A/H1N1 pandemic influenza
- = PBSA = seasonal H1N1F = seasonal H1N1 + MF59C = pdm H1N1C+ = pdm H1N1 + MF59
Vaccines
ESCMID Online Lecture Library
© by author
Preliminary immunogenicity results post-dose one exceed the regulatory threshold
Devaster JM. et al. Immunogenicity and safety of an A/H1N1v AS03A-adjuvanted pandemic influenza vaccine candidate: Preliminary results from a randomized, controlled trial in adults. Vaccine Congress 2009, Singapore.
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
D0 D21 D0 D21
SCRSPRGMT
% s
ubje
cts
% s
ubje
cts
H1N1 (21µg)H1N1 (5.25µg)+
AS03A
D21 D211
10
100
1000
D0 D21 D0 D21
H1N1 (21µg)H1N1 (5.25µg)+
AS03A
H1N1 (21µg)H1N1 (5.25µg)+
AS03A
Prior to receipt of official regents vaccines were formulated using an alternative assay for HA content. HA potencies were then retested by SRD once calibrated reagents were available.
ESCMID Online Lecture Library
© by author
ADJUVANTS AND FLU VACCINES
Seasonal flu-vaccine~ Annual boosting of primed individuals (limited effect)
~ Yearly administration of alum may carry risks~ FLUAD (MF59, Novartis) for elderly: > longevity antibody
Pandemic flu-vaccine does it require adjuvant? ~ Priming of non-exposed individuals~ Without adjuvant larger doses of antigen required (90 ug: H5N1)~ Adjuvant can enhance capacity (5 to 15-fold dose reduction)
~ Little effect in primed individuals (H1N1 vs H5N1)
POINTS TO CONSIDER
ESCMID Online Lecture Library
© by author
Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets: WHO initiative
Stittelaar et al. submitted
ESCMID Online Lecture Library
© by author
New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and TherapeuticEfficacy in Ferrets Friesen R.H. et al, PLoS One. 2010
ESCMID Online Lecture Library
© by author
Two vaccination effectivenes studies "Mexican flu"
The Scottish VIPER study and a German study
vaccination was effective 97% in 15-65 age group83% in > 65 age group
vaccination reduced risk of Influenza vaccination reduced risk of pneumonia and hospitalisationvaccination reduced mortality
Additional data report that the vaccines were safe!!!ESCMID Online Lectu
re Library
© by author
Germany: Effectiveness of GSK’s AS03-adjuvanted pandemic H1N1 2009 vaccine
O. Wichmann, P. Stöcker, G. Poggensee, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates effectiveness in Germany 2009-2010. Euro Surveillance 2010.
289 H1N1 cases with complete data:- 228 cases were vaccinated < 14 days before onset of symptoms- 61 cases were vaccinated > 14 days before onset of symptoms
ESCMID Online Lecture Library
© by author
Direct effectiveness of GSK’s AS03-adjuvanted pandemic H1N1 2009 vaccine
German data:
Persons 14 to 59 years: 96,8%Persons ≥ 60 years: 83,3%
Scottish data:
At risk persons (all ages): 95,0%
Canadian data:
Children 36 months to < 10 years: 100%ESCMID Online Lectu
re Library
© by author
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
Karl G Nicholson et al., The Lancet Infectious Diseases, 2011
AS03A-adjuvanted vaccine was more immunogenic against pandemic influenza A H1N1 virus than whole-virion vaccine and offers greater antigen-sparing capacity. A two-dose strategy should be considered for older people.
ESCMID Online Lecture Library
© by author
Available at: http://www.patriotsaints.com. Last accessed 02 November 2010.
In the lay press pandemic vaccines 2009 were said to be unsafe
ESCMID Online Lecture Library
© by author
Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France
Caillet et al. Eur J Clin Pharmacol, 2010
ESCMID Online Lecture Library
© by author
Conclusion by the EMA:
“The CHMP re-assessed the benefit-risk profile of Celvapan [Baxter], Focetria [Novartis] and Pandemrix [GSK]. Taking into account the comprehensive information available on the clinical safety and efficacy of these vaccines, the CHMP concluded that
the benefit-risk profile continues to be positive.
Consequently, the CHMP recommended the further use of the vaccines within the EU in the authorised indication even after the pandemic was declared over.”ESCMID Online Lectu
re Library
© by author
European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy (23 September 2010)
“As per 17 September 2010, there are 81 reports from healthcare professionals suggestive of narcolepsy, all collected through spontaneous reporting systems.” “The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) agreed that at present the benefit-risk balance for Pandemrix continues to be positive, and that while the review is still ongoing there was no need for Europe-wide restrictions on use.”“Available evidence does not confirm a link; more research needed.”Recently new data from Finland and other Scandinavian countries emerged(genetic predisposition, latitude association, geographical restriction, 9x increased incidence: report Finland …). EMA and European studies ongoing!
European Medicines Agency. Press release 23 September 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096998.pdf.
ESCMID Online Lecture Library
© by author
Pandemic H1N1 virus… …what may happen next?
Co-circulation with other influenza viruses
(e.g. H3N2 and avian H5N1)
Change virulence (re-assortment or mutation)
Acquire antiviral resistance (re-assortment or mutation)
Circulate as seasonal flu virus
THERE WILL BE ANOTHER FLU PANDEMIC: H5N1…?ESCMID Online Lectu
re Library
© by author
Influenza research at Erasmus MC- The team leaders -
Prof. Dr. R.A.M. Fouchier Virology
Prof. Dr. T. Kuiken Pathology
Prof. Dr. M. Koopmans Epidemiology
Prof. Dr. C.A.B. Boucher Antiviral research
Dr.A.van der Eijk / Dr.P.Fraaij Clinical research
Prof.Dr. G.F. Rimmelzwaan Immunology
Dr. M. Schutten Diagnostics
Dr. A. Andeweg Genomics
ESCMID Online Lecture Library
© by author
Influenza research at Erasmus MC
- collaborations -
Erasmus MC VirologyVincent MunsterEmmie de WitDebby van RielTheo BestebroerGer van der WaterGeert van AmerongenRobert Dias d’UlloisMarion KoopmansMartin SchuttenJan de JongCharles BoucherAnnemiek van der EijkPieter FraaijGuus RimmelzwaanBart HaagmansThijs KuikenRon FouchierAb Osterhaus
Viroclinics- Biosciences BVKoert StittelaarRob van LavierenLeon de WaalCarel van BaalenFemkeBerkhoffEdwin Veldhuis-KroezeLeo SprongPaul ZoeteweijJames Simon… many others.Sanofi PasteurGSKRocheNovartisSolvayNobilonCrucellet al.
ESCMID Online Lecture Library
© by author
Top Related